Sex Bias and Underutilization of Lipid-Lowering Therapy in Patients With Coronary Artery Disease at Academic Medical Centers in the United States and Canada
Open Access
- 14 February 2000
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 160 (3) , 343-347
- https://doi.org/10.1001/archinte.160.3.343
Abstract
DURING the past 5 years, randomized clinical trials have provided unequivocal evidence that cholesterol-lowering therapies reduce initial and recurrent cardiovascular events.1-5 These studies are consistent with the National Cholesterol Education Program's (NCEP's) recommendations for dietary and pharmacological therapy in subjects at highest risk of coronary artery disease (CAD). While previous reports evaluating the use of hypolipidemic therapy have generally reported low treatment rates by cardiologists6 and primary care physicians,7,8 there have been limited prospective data evaluating the use of lipid-lowering therapy (LLT) in men and women with CAD. We hypothesized that treatment rates for elevated cholesterol would be considerably higher in academic medical centers, which are heavily employed in clinical research protocols for the secondary prevention of cardiovascular disease. Therefore, we collected data from the Prospective Randomized Evaluation of the Vascular Events of Norvasc Trial (PREVENT) to further examine this issue.This publication has 1 reference indexed in Scilit: